LawFinder.news
LawFinder.news

Bombay High Court Grants Interim Injunction in Trademark Dispute Over Pharmaceutical Products "GEMCAL" vs. "GEXCAL"

LAW FINDER NEWS NETWORK | |
Bombay High Court Grants Interim Injunction in Trademark Dispute Over Pharmaceutical Products "GEMCAL" vs. "GEXCAL"

Court highlights deceptive similarity and public health risks, restraining Syngex Pharma from using "GEXCAL" mark pending final hearing


In a significant interim order dated October 29, 2026, the Bombay High Court, presided over by Justice Madhav J. Jamdar, granted ad-interim relief to Alkem Laboratories Ltd. in a trademark infringement and passing off suit against Syngex Pharma Private Limited. The dispute centers around the plaintiff's registered trademark "GEMCAL" and the defendant's mark "GEXCAL," both used for pharmaceutical products.


The Court observed that the marks "GEMCAL" and "GEXCAL" are deceptively similar visually, phonetically, and structurally. The key difference between the two is the substitution of the letter "M" with "X," a minimal variation insufficient to dispel the likelihood of confusion among consumers. Both products contain similar generic medicinal compositions, including Calcitriol, Calcium Carbonate, and Zinc Sulfate, commonly prescribed for nutritional deficiencies and bone health.


Justice Jamdar emphasized the critical public interest element in cases involving medicinal products, referencing the Supreme Court's ruling in Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd. (2001) 5 SCC 73. The Court noted that confusion in such cases could lead to serious health risks, mandating greater caution.


The plaintiff, Alkem Laboratories, demonstrated longstanding use and reputation of its "GEMCAL" mark since 2000, supported by multiple trademark registrations, promotional expenditures, and sales turnover certificates. The defendants had earlier abandoned an opposition to the plaintiff's challenge of their initial 2018 trademark application for "GEXCAL" but resumed use without resolving the dispute, prompting legal action.


With the defendants failing to appear or contest the claims, the Court found a strong prima facie case of trademark infringement and passing off, justifying the injunction. The order restrains Syngex Pharma, its affiliates, and agents from manufacturing, selling, advertising, or otherwise using the "GEXCAL" mark or any deceptively similar mark in relation to pharmaceutical products until the final disposal of the suit.


The Court directed the defendants to file their reply within four weeks and the plaintiff to file rejoinder two weeks thereafter, setting the next hearing for December 17, 2026.


This ruling underscores the judiciary's firm stance on protecting trademark rights in the pharmaceutical sector, balancing commercial interests with the paramount concern of safeguarding public health.


Bottom Line:

Trade Mark Infringement and Passing Off - Interim relief granted in favor of the plaintiff in relation to pharmaceutical products due to deceptive similarity between the rival marks "GEMCAL" and "GEXCAL," emphasizing public health concerns and likelihood of confusion.


Statutory provision(s):

Trade Marks Act, 1999 Sections 28, 29; Companies Act, 1956.


Alkem Laboratories Ltd. v. Syngex Pharma Private Limited, (Bombay) : Law Finder Doc Id # 3023090

Share this article: